Beijing Minhai Biotechnology Therapeutic Pipeline Market Review, H2 2017

PUNE, INDIA, January 19, 2017 /EINPresswire.com/ -- Beijing Minhai Biotechnology Co Ltd - Product Pipeline Review - 2016

Summary
The report provides comprehensive information on the therapeutics under development by Beijing Minhai Biotechnology Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/889100-beijing-minhai-biotechnology-co-ltd-product-pipeline-review-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Beijing Minhai Biotechnology Co Ltd
- The report provides overview of Beijing Minhai Biotechnology Co Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Beijing Minhai Biotechnology Co Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Beijing Minhai Biotechnology Co Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy
- Evaluate Beijing Minhai Biotechnology Co Ltd’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Beijing Minhai Biotechnology Co Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Beijing Minhai Biotechnology Co Ltd’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Content: Key Points
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Beijing Minhai Biotechnology Co Ltd Snapshot 7
Beijing Minhai Biotechnology Co Ltd Overview 7
Key Facts 7
Beijing Minhai Biotechnology Co Ltd - Research and Development Overview 8
Key Therapeutic Areas 8
Beijing Minhai Biotechnology Co Ltd - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Beijing Minhai Biotechnology Co Ltd - Pipeline Products Glance 16
Beijing Minhai Biotechnology Co Ltd - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
Beijing Minhai Biotechnology Co Ltd - Clinical Stage Pipeline Products 18
Phase I Products/Combination Treatment Modalities 18
Beijing Minhai Biotechnology Co Ltd - Early Stage Pipeline Products 19
IND/CTA Filed Products/Combination Treatment Modalities 19
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/889100-beijing-minhai-biotechnology-co-ltd-product-pipeline-review-2016


Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here